Table 4.
Investigational trials examining the efficacy of TAAs or peptides in treating cancer patients.
| Cancer Type | Trial Phase | Action | TAAs | Notes | Trial No. |
|---|---|---|---|---|---|
| Bladder carcinoma | I | Completed | PPV | Atezolizumab with Hiltonol® adjuvanted intervention |
NCT03359239 |
| Brain tumor | I | Recruiting | Multiple | Varlilumab with Hiltonol® adjuvanted intervention | NCT02924038 |
| Breast carcinoma | I/II | Completed | FOLR1 | Combined with cyclophosphamide and GM-CSF | NCT02593227 |
| Breast carcinoma | II | Active | FOLR1 | Combining GM-CSF-adjuvanted therapy with cyclophosphamide |
NCT03012100 |
| Breast carcinoma | II | Recruiting | HER2 | Combined with GM-CSF | NCT02636582 |
| Breast carcinoma | I | Active | Multiple | Durvalumab in combination with the adjuvanted interventions of montanide, ISA-51, and Hiltonol® |
NCT02826434 |
| Breast carcinoma | I | Active | Multiple | Added to pembrolizumab | NCT03362060 |
| Breast carcinoma Gastric carcinoma |
I | Completed | HER2 | Intervention with GM-CSF, imiquimod, and cyclophosphamide |
NCT02276300 |
| CRC | I | Completed | Multiple | Chemotherapy in addition to a montanide ISA-51- adjuvanted intervention |
NCT03391232 |
| Glioblastoma | I/II | Completed | WT1 | Only one adjudicated agent | NCT02750891 |
| Glioblastoma | II | Recruiting | WT1 | Added to bevacizumab | NCT03149003 |
| Glioma | I | Completed | IDH1 | ISA-51 adjuvanted with montanide | NCT02454634 |
| Glioma | I | Recruiting | H3 | Adjuvanted with montanide ISA-51 and Hiltonol® | NCT02960230 |
| Glioma | II | Recruiting | n.a. | In conjunction with Hiltonol® | NCT02358187 |
| HCC | I/II | Completed | Multiple | Combined with cyclophosphamide and CV8102- adjuvant intervention |
NCT03203005 |
| HPV tumor | I | Completed | p16 | ISA-51 adjuvanted with montanide | NCT02526316 |
| Kidney cancer | I | Recruiting | PPV | Ipilimumab with Hiltonol® adjuvanted intervention | NCT02950766 |
| Kidney cancer | I/II | Unknown | Multiple | Montanide ISA-51 and GM-CSF were added | NCT02429440 |
| Leukemia | I | Recruiting | PPV | Intervention with Hiltonol® adjuvant and cyclophosphamide |
NCT03219450 |
| Leukemia | I | Unknown | Multiple | Montanide ISA-51 and GM-CSF were added as adjuvants |
NCT02240537 |
| Leukemia | II | Recruiting | PPV | Lenalidomide with imiquimod adjuvant | NCT02802943 |
| Lung cancer | I | Recruiting | PPV | Intervention with Hiltonol® adjuvant and pembrolizumab, cisplatin as well as pemetrexed |
NCT03380871 |
| MDS | I/II | Completed | WT1 | Only one adjudicated agent | NCT02436252 |
| Melanoma | n.a. | Completed | MART-1 | Only one adjuvanted agent | NCT02320305 |
| Melanoma | I | Completed | Multiple | Combined with GM-CSF | NCT02696356 |
| Melanoma | I/II | Recruiting | Multiple | When used with trametinib and dabrafenib | NCT02382549 |
| Melanoma | I/II | Terminated | Multiple | Ipilimumab and montanide ISA-51 adjuvanted intervention |
NCT02385669 |
| Melanoma | I/II | Terminated | Multiple | Combining cyclophosphamide with the adjuvanted interventions of montanide ISA-51 and Hiltonol® | NCT02425306 |
| Melanoma | I/II | Completed | Multiple | Added to pembrolizumab | NCT02515227 |
| Melanoma | I/II | Recruiting | IDO1 and PD-L1 | Nivolumab in addition to a montanide ISA-51- adjuvanted intervention |
NCT03047928 |
| Melanoma | II | Completed | NY-ESO-1 and MART-1 | Combining DC vaccination with a montanide ISA-51 and Hiltonol® adjuvanted intervention | NCT02334735 |
| Myeloma | I | Completed | PD-L1 | ISA-51 adjuvanted with montanide | NCT03042793 |
| Myeloma | I | Recruiting | Multiple | Lenalidomide, durvalumab, and intervention with Hiltonol® adjuvant | NCT02886065 |
| NSCLC | I/II | Active | UCP2 and UCP4 | ISA-51 adjuvanted with montanide | NCT02818426 |
| Ovarian cancer | II | Completed | FOLR1 | In addition to durvalumab | NCT02764333 |
| Ovarian cancer | II | Terminated | FOLR1 | Combined with GM-CSF | NCT02978222 |
| Prostate cancer | I | Completed | BCL-XL | Combined with the drug montanide CAF09b | NCT03412786 |
| Prostate cancer | I/II | Unknown | PSA | Intervention with GM-CSF or montanide ISA-51 adjuvant and hyperthermia, imiquimod, or RNA-based vaccine |
NCT02452307 |
| Prostate cancer | I/II | Completed | RHOC | Adjuvant: montanide ISA-51 | NCT03199872 |
| Prostate cancer | II | Completed | TERT | Montanide ISA-51 and imiquimod were used as adjuvants. |
NCT02293707 |
| Solid tumor | I | Completed | PPV | Combination of Hiltonol® adjuvanted intervention and nivolumab | NCT02897765 |
| Brain tumor | I | Recruiting | Multiple | GM-CSF and montanide ISA-51 adjuvanted intervention in combination with temozolomide |
NCT03299309 |
| Brain tumor | I | Withdrawn | PPV | Combined with Hiltonol® | NCT03068832 |
| Gastroesophageal cancer | I/II | Active | HER2 | When used in conjunction with cisplatin and 5-fluorouracil or capecitabine |
NCT02795988 |